FDA accepts first letter of intent (LOI) into the ISTAND Pilot Program for an organ-on-a-chip technology, a type of micro-physiological system (MPS), to study drug-induced liver injury (DILI) for certain drug candidates.
Similar Posts
Mobile Power Unit AC Power Cord Recall: Abbott Medical Removes AC Power Cord Associated with HeartMate Mobile Power Unit (MPU) Due to Potential Risk of the Cord Not Locking into Place
Abbott Medical is removing power cords associated with the HeartMate Mobile Power Unit due to a potential risk of the cord not locking into place.Asahi Kasei Finechem Co., Ltd. – 11/14/2025
Asahi Kasei Finechem Co., Ltd. – 11/14/2025. Country: Japan. Record Type: 483COSMO KOREA – 11/03/2025
Unapproved New Drugs/Misbranded/BotoxJuly 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement – 07/18/2025
July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting AnnouncementA.S.K. Foods, LLC Issues Allergy Alert on Undeclared Soy in Publix Rice & Pigeon Peas
A.S.K. Foods, LLC of Palmyra, PA is recalling select 32 oz. containers of Publix Rice & Pigeon Peas because it contains undeclared soy. People who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening allergic reaction if they consume this product.FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease
The FDA granted supplemental approval to Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication.